Csl Limited

Csl Behring Gmbh

Csl Behring Lengnau Ag

Michael Wilson

Con Panousis

Veronika Rayzman

Andrew Donald Nash

Marc Nolte

Stefan Schmidbauer

Matthew Hardy

Steve Dower

Dallas Hartman

Kirsten Edwards

Kerstin Emmrich

Arna Andrews

Mathew Hardy

Matthew Philip Hardy

Kirsten Mae Edwards

The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.

Methods of administering inhibitory anti-factor XII/XIIa monoclonal antibodies

The present invention provides a modified polypeptide which binds Factor VIII. The polypeptide comprises truncated von Willebrand Factor (VWF) which comprises a sequence as shown in SEQ ID NO:3 or a fragment thereof or a sequence 90% identical thereto, wherein the truncated VWF comprises at least one modification in comparison to SEQ ID NO: 3 in at least one position selected from the group consisting of SI, S3, LI 8, V42, S43, K149, N248, S279, V320, T325, Q395 and K418.

Mutated truncated von Willebrand Factor

The present invention provides a modified polypeptide which binds Factor VIII. The modified polypeptide comprises a sequence as shown in SEQ ID NO:3 in which the sequence comprises at least one modification at a position selected from the group consisting of L18, V42, K149, N248, S279, V320, T325, Q395 and K418 such that the modified polypeptide binds to Factor VIII with an off rate lower than a reference polypeptide comprising an unmodified SEQ ID NO:3.

Mutated von Willebrand factor

Methods of administering inhibitory anti-factor XII/XIIA monoclonal antibodies

The present invention provides a modified polypeptide which binds Factor VIII. The modified polypeptide comprises a sequence as shown in SEQ ID NO:3 in which the sequence comprises at least a modification at position 1 or 3 such that the modified polypeptide binds to Factor VIII with an off rate at least 5 fold lower than a reference polypeptide comprising an unmodified SEQ ID NO:3.

Modified von Willebrand Factor

Nucleic acids encoding inhibitory anti-factor XII/XIIa monoclonal antibodies

The present disclosure provides proteins comprising antigen binding sites of antibodies that bind to interleukin-11 (IL-11) receptor alpha (IL-11R&#x3b1;) and uses thereof, e.g., in therapy.

Fibronectin III domain of IL-11R&#x3b1;

Inhibitory anti-factor XII/XIIA monoclonal antibodies and their uses

IL-11R binding proteins

Growing community of inventors

Elwood, Australia

Michael Wilson